{
Novartis AG

Companies

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-312025-03-312025-04-032025-04-03115118866442200
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-312025-03-312025-04-032025-04-03421118866442200
Download SVG
Download PNG
Download CSV

UBS maintains buy rating for Novartis with price target of 111 francs

UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs. Analyst Matthew Weston noted that the pharmaceutical company's new medium-term targets reflect strong confidence, significantly exceeding market consensus.
boerse.de
Swiss Franc UBS Novartis AG CHE Matthew Weston
TradFi, Market Report
09:28 21.11.2024

vartis ag reports strong sales across diverse therapeutic areas and regions

Novartis AG is a leading global pharmaceutical company, with sales primarily in oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). By the end of 2023, it will operate 33 production sites worldwide, with sales distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
Zonebourse
United States Dollar Novartis AG USA CAN CHE Show more
TradFi, Market Report
09:14 21.11.2024

global pediatric healthcare market poised for significant growth through 2032

The Global Pediatric Healthcare market is projected to grow from $175.6 billion in 2024 to $290 billion by 2032, with a CAGR of 6.5%. Key players include Abbott, Pfizer, and Merck, focusing on pharmaceuticals, nutrition, medical devices, and vaccines across various applications like hospitals and homecare. The market is expanding rapidly in the Asia-Pacific region, while North America remains the dominant market.
openPR.com
Siemens Healthineers AG Pfizer Inc. Medtronic Johnson & Johnson Danone S.A. Philips Merck & Co., Inc. GlaxoSmithKline Nestlé S.A. The Procter & Gamble Company GE HealthCare Technologies Inc. Reckitt Benckiser Group plc Bristol-Myers Squibb Company Sanofi Boston Scientific Corporation Hoffmann-La Roche AG Abbott Novartis AG Bayer USA IND VNM THA IDN SGP MYS JPN KOR HKG AUS PHL TWN CHN Nidhi Bhawsar Show more
Healthcare, Market Report
17:31 20.11.2024

ura and dexcom partner to enhance metabolic health tracking for users

Eli Lilly"s experimental cholesterol pill, muvalaplin, has shown promising results in a mid-stage trial, significantly reducing levels of lipoprotein(a), a genetic risk factor for heart disease. The highest dose decreased Lp(a) by 70% compared to placebo, with a favorable safety profile. Analysts suggest the drug could become a blockbuster if it proves effective in preventing cardiovascular events in future trials.
CNBC
Novartis AG DexCom, Inc. Veritone, Inc. Eli Lilly and Company Oura USA Matt Dolan Ruth Gimeno Annika Constantino David Risinger Tom Hale Show more
Healthcare, News Article
22:04 19.11.2024

pharmaceutical industry struggles to improve access to medicine in low-income countries

Pharmaceutical companies are increasingly focusing on access to medicines in low-income countries, with Novartis leading the way by integrating access plans into 96% of its late-stage drug projects. However, many companies still prioritize the US market, resulting in limited availability of essential medicines globally. Roche aims to double patient treatment numbers in low-income regions by 2026, yet significant gaps in transparency and patient reach persist across the industry.
SWI swissinfo.ch
Bristol-Myers Squibb Company GSK plc Hoffmann-La Roche AG AbbVie Inc. Sanofi Novo Nordisk A/S Novartis AG Johnson & Johnson Pfizer Inc. GBR CHE NLD Jayasree Iyer Sabastine Wakdok Show more
Healthcare, Market Report
14:30 19.11.2024

global hashimoto thyroiditis market projected to reach 12.6 billion by 2033

The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.
Spherical Insights
United States Dollar Amgen Inc. Merck & Co., Inc. Novartis AG Sanofi Mylan N.V. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Company Takeda Pharmaceuticals Limited Company Bayer AG Pfizer Inc. Roche Holding AG AbbVie Inc. AstraZeneca PLC Eli Lilly and Company Glaxosmithkline plc ARG GBR FRA ITA KOR ZAF MEX USA BRA ESP SAU CAN QAT ARE JPN AUS DEU CHN RUS IND Pfizer Inc. AbbVie Inc. Mylan N.V. Inc. Merck & Co GlaxoSmithKline plc Show more
Healthcare, Market Report
04:38 19.11.2024

regenerative medicine market projected to reach 349 billion by 2033

The global regenerative medicine market is projected to grow from USD 31.90 billion in 2023 to USD 349.93 billion by 2033, with a CAGR of 27.06%. Cell therapy leads in market share, while musculoskeletal conditions are expected to grow the fastest. North America dominates the market due to advanced healthcare infrastructure and increased funding for research and development.
Spherical Insights
United States Dollar Novartis AG Hoffmann-La Roche AG Johnson & Johnson ReNeuron Pfizer Inc. USA GBR AUS KOR CHN IND BRA ITA MEX FRA ESP ZAF JPN DEU ARE CAN Dr. Samuel Lynch Samuel Lynch Pfizer Lynch Johnson & Johnson Show more
Healthcare, Market Report
04:37 19.11.2024

Swiss companies commit to science based targets for CO2 reduction

A total of 224 Swiss companies have committed to CO2 reduction targets aligned with the Paris Climate Agreement by joining the Science Based Targets initiative (SBTi). This includes major corporations like ABB, Givaudan, and Nestlé, with over 80 new members since the start of the year. Only three companies have withdrawn from the initiative.
SWI swissinfo.ch
Novartis AG Nestlé S.A. Givaudan SA Holcim AG ABB Ltd CHE Nestlé Holcim Givaudan Novartis ABB Show more
Regulatory & Legal, News Article
11:11 16.11.2024

swiss stock market faces downturn amid us interest rate concerns

The Swiss stock market remains in a bearish trend, with the SMI Guiding Values Index down 1.08% to 8174.97 points, influenced by concerns over potential U.S. interest rate hikes. Major banks like UBS and Credit Suisse faced significant losses, while defensive stocks like Nestlé and Novartis attempted to mitigate the downturn. Kudelski saw a positive turn with a court victory against China's Gotech, while Adienne announced plans to enter the stock market without further details.
TicinoNews
United States Dollar Richemont DNS Inc. Julius Bär Stiftung Novartis AG Hoffmann-La Roche AG Swiss Life Holding AG Swatch AG ADIENNE SA Credit Suisse Anlagestiftung Gotech Swiss Re AG Zurich Insurance Group AG ABB Ltd Geberit AG UBS AG Kudelski SA LafargeHolcim Ltd. Nestlé S.A. Adecco Group AG CHE Eric Rosengren Show more
TradFi, Market Report
18:34 15.11.2024

swiss stock exchange declines as investors react to us interest rate concerns

The Swiss stock exchange closed lower, with the SMI down 0.70% at 8206.20 points, following concerns over potential U.S. interest rate hikes. Major banks like UBS and Credit Suisse faced significant losses, while defensive stocks like Nestlé and Novartis attempted to mitigate the downturn. Market experts anticipate a turbulent period ahead after recent volatility in U.S. markets.
TicinoNews
Swiss Franc Richemont DNS Inc. Swisscom AG Julius Bär Stiftung Novartis AG Actelion Ltd. Hoffmann-La Roche AG Swiss Life Holding AG Swatch AG ADIENNE SA Credit Suisse Anlagestiftung Swiss Re AG Zurich Insurance Group AG SGS SA ABB Ltd Geberit AG UBS AG Syngenta AVC SA Kudelski SA LafargeHolcim Ltd. Nestlé S.A. Adecco Group AG Givaudan SA CHE Eric Rosengren Neel Kashkari Dennis Lockhart Show more
TradFi, Market Report
17:32 15.11.2024
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Global Trade Developments Global Financial Events Finance Mergers & Acquisitions Banking Regulations Retail and Consumer Goods Startups & Entrepreneurship Central Bank Actions Industry Mergers & Acquisitions Inflation and Monetary Impact Government Economic Policies CEO Changes Market Analysis and Predictions Domestic Politics Government Policies Workplace Trends GDP Growth & Recession Forecasts Financial Scams and Security
Countries:
USA CHN CHE GBR IND DEU FRA JPN CAN VNM ESP ITA ARE SGP MEX TWN AUS THA MYS EGY
Companies:
JPMorgan Chase & Co. Apple Inc. Tesla, Inc. Barclays PLC Deutsche Bank Money Market PP The Goldman Sachs Group, Inc. Credit Suisse Strategic Income I Banco Santander, S.A. Berkshire Hathaway Inc. UBS Group AG Lloyds Banking Group plc SpaceXCoin USD Morgan Stanley Amazon.com, Inc. Bank of America Corporation Wells Fargo & Company BNP Paribas SA NVIDIA Corporation Bank Frick AG UniCredit S.p.A.
Currencies:
United States Dollar Euro Swiss Franc British Pound Sterling Japanese Yen Indian Rupee Chinese Yuan Vietnamese Đồng South Korean Won Canadian Dollar Australian Dollar Thai Baht New Taiwan Dollar Singapore Dollar Indonesian Rupiah Mexican Peso Cambodian Riel Russian Ruble Hong Kong Dollar Offshore Chinese Yuan
People:
Donald Trump Elon Musk Warren Buffett JD Vance Sergio Ermotti Mark Haefele Robin Leopold Olivier Calvet Troy L Rohrbaugh Jennifer Piepszak Karoline Leavitt Ursula von der Leyen Scott Bessent Stacey Friedman George Saravelos Alex Kramm Susan P. Crawford Francois Xavier Bouvignies Joseph Spak Stefan Rauti

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.